BJU International:吸烟会增加患者接受前列腺癌治疗的风险

2015-02-03 MedSci MedSci原创

图 1 前列腺特异性抗原无复发存活率(P=0.003) 图2  吸烟情况的无癌转移存活结果 图3 吸烟与胃溃疡毒性(P=0.02) 在前列腺癌患者中,接受治疗的吸烟患者有增加副作用的风险,并且未来有癌症复发的可能性,甚至会死于前列腺癌。研究结果发表在《英国泌尿科期刊》上,研究表明吸烟可能对前列腺癌患者的健康状况产生负面影响,并导致相关的并发症。 几项研究已经证实吸烟和

图 1 前列腺特异性抗原无复发存活率(P=0.003)

图2  吸烟情况的无癌转移存活结果

图3 吸烟与胃溃疡毒性(P=0.02)

在前列腺癌患者中,接受治疗的吸烟患者有增加副作用的风险,并且未来有癌症复发的可能性,甚至会死于前列腺癌。研究结果发表在《英国泌尿科期刊》上,研究表明吸烟可能对前列腺癌患者的健康状况产生负面影响,并导致相关的并发症。

几项研究已经证实吸烟和前列腺癌之间的联系。为了更好地理解吸烟对前列腺癌发展进程和治疗的影响,纽约纪念斯隆凯特林癌症中心放射肿瘤学教授医学博士Michael Zelefsky和他的同事研究了1988年到2005年之间2358例接受外部光束放射治疗前列腺癌的患者。其中,2156名有吸烟史。患者将不吸烟者,当前吸烟者,先前吸烟者,当前吸烟未知者进行分类。

随访近八年来,当前吸烟的患者相比于从未吸烟的患者,癌症复发风险增加了40%,癌症扩散和死亡的风险也增加了近2倍。此外,当前吸烟的患者和先前吸烟的患者出现副作用的可能性较高,如尿毒性等。

当前吸烟的患者会显著增加前列腺特异抗原复发的风险(危害比 HR 1.4, P = 0.02),转移的风险(HR 2.37, P < 0.001),前列腺癌死亡的风险(HR 2.25, P < 0.001)。多变量分析表明,吸烟与放射治疗相关的生殖泌尿毒性的风险增加也有关联(当前吸烟的患者,HR 1.8,P = 0.02;先前吸烟的患者 HR 1.45,P = 0.01)。吸烟不会增加胃肠道毒性。

原始出处

Emily Steinberger, Marisa Kollmeier, Sean McBride, Caroline Novak, Xin Pei, Michael J. Zelefsky. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity. BJU International, 2015; DOI: 10.1111/bju.12969\

本文是MedSci编译,转载请注明出处,非常感谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=59918, encodeId=b3e55991818, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59919, encodeId=05c05991974, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33895, encodeId=401333895cb, content=戒烟难, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Thu Jul 30 22:55:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880484, encodeId=9a04188048449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 16 10:17:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008712, encodeId=a2a42008e12c9, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Feb 26 06:17:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15017, encodeId=b8c81501e0e, content=这个研究有特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Tue Feb 03 18:27:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=59918, encodeId=b3e55991818, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59919, encodeId=05c05991974, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33895, encodeId=401333895cb, content=戒烟难, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Thu Jul 30 22:55:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880484, encodeId=9a04188048449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 16 10:17:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008712, encodeId=a2a42008e12c9, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Feb 26 06:17:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15017, encodeId=b8c81501e0e, content=这个研究有特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Tue Feb 03 18:27:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=59918, encodeId=b3e55991818, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59919, encodeId=05c05991974, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33895, encodeId=401333895cb, content=戒烟难, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Thu Jul 30 22:55:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880484, encodeId=9a04188048449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 16 10:17:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008712, encodeId=a2a42008e12c9, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Feb 26 06:17:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15017, encodeId=b8c81501e0e, content=这个研究有特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Tue Feb 03 18:27:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-07-30 sanshengshi

    戒烟难

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=59918, encodeId=b3e55991818, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59919, encodeId=05c05991974, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33895, encodeId=401333895cb, content=戒烟难, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Thu Jul 30 22:55:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880484, encodeId=9a04188048449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 16 10:17:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008712, encodeId=a2a42008e12c9, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Feb 26 06:17:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15017, encodeId=b8c81501e0e, content=这个研究有特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Tue Feb 03 18:27:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-05-16 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=59918, encodeId=b3e55991818, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59919, encodeId=05c05991974, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33895, encodeId=401333895cb, content=戒烟难, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Thu Jul 30 22:55:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880484, encodeId=9a04188048449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 16 10:17:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008712, encodeId=a2a42008e12c9, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Feb 26 06:17:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15017, encodeId=b8c81501e0e, content=这个研究有特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Tue Feb 03 18:27:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-02-26 般若傻瓜
  6. [GetPortalCommentsPageByObjectIdResponse(id=59918, encodeId=b3e55991818, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59919, encodeId=05c05991974, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:12:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33895, encodeId=401333895cb, content=戒烟难, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cab51623450, createdName=sanshengshi, createdTime=Thu Jul 30 22:55:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880484, encodeId=9a04188048449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat May 16 10:17:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008712, encodeId=a2a42008e12c9, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Feb 26 06:17:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15017, encodeId=b8c81501e0e, content=这个研究有特色, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=223.104.5.**, createdTime=Tue Feb 03 18:27:00 CST 2015, time=2015-02-03, status=1, ipAttribution=)]
    2015-02-03 223.104.5.**

    这个研究有特色

    0

相关资讯

Ann Epidemiol:美国三成癌症患者死于吸烟

近日,发表在国际杂志the Annals of Epidemiology上的一篇研究报告中,来自艾默里大学(Emory University )的研究人员表示,当前在美国尽管吸烟率明显下降了,但是在10个癌症死亡个体中就有3个死于烟草,因此努力降低吸烟在美国的流行将是未来抑制个体因癌症死亡的重中之重。 早在30年前来自英国的研究者就进行了相关的研究分析,并发现在所有的癌症死亡病例中大约有30%的

PNAS:吸烟与戒酒

一项研究提示,吸烟可能阻断延长的戒酒期间大脑的γ-氨基丁酸A(GABAA)受体的恢复。吸烟在酒精依赖的吸烟者的戒酒期间出现的神经适应与行为变化的作用仍然不清楚,更好地理解烟草在戒酒中的作用可能对于设计治疗策略有价值。 Kelly P. Cosgrove及其同事对52名人类和13只雄性恒河猴进行了研究,从而调查吸烟和尼古丁对戒酒期间的γ-氨基丁酸A(GABAA)受体可利用性变化的作用。大脑成像表

健康生活方式可帮助减少癌症发生

据国外媒体报道,英国癌症研究中心的最新研究发现,对癌症有着突出影响的生活方式包含了一些常见的怀疑因素,比如抽烟、肥胖和喝酒。该机构最新提供的癌症数据表明,位于第一位的风险因素就是抽烟。 对于吸烟的研究,英国癌症研究中心的科学家们已经发现了肺部的癌症如何能够快速传播。研究人员拍摄的显微图像肺癌细胞中连接细胞的蛋白质链已经断裂。这就意味着它们能够摆脱并且轻易传播。 除了吸烟之外,该机构

Tob Control:不吸烟更快乐?

美国食品药品监督管理局对已制定法规中有关评估的内容制定了一项政策,规定减少吸烟量可大幅度贴现医疗保险保单,因为吸烟者不再吸烟后其快乐感可能会减弱。2015年1月6日发表在Tobacco control上的一项研究,采用前苏联(fSU)九个国家的数据,探讨了高吸烟频率(男性)和吸烟相关死亡率之间的相关性。 数据来自2010-2011年在亚美尼亚、阿塞拜疆、白俄罗斯、格鲁吉亚、哈萨

PNAS:吸烟对戒酒有影响

一项研究提示,吸烟可能阻断延长的戒酒期间大脑的γ-氨基丁酸A(GABAA)受体的恢复。吸烟在酒精依赖的吸烟者的戒酒期间出现的神经适应与行为变化的作用仍然不清楚,更好地理解烟草在戒酒中的作用可能对于设计治疗策略有价值。 Kelly P. Cosgrove及其同事对52名人类和13只雄性恒河猴进行了研究,从而调查吸烟和尼古丁对戒酒期间的γ-氨基丁酸A(GABAA)受体可利用性变化

Diabetes Care:吸烟与2型糖尿病长期风险研究(欧洲人群EPIC-InterAct研究)

研究者对吸烟和2型糖尿病发生之间的关系进行了研究,对于大量的潜在混合因素进行分析,并探讨了潜在的效应修饰和中介因素。研究表明,与不吸烟的男性和女性相比,曾经吸烟和目前吸烟是2型糖尿病的发生相关的高风险因素,其独立于教育水平、体力活动、饮酒、饮食。因此,吸烟可作为2型糖尿病的一个危险因素,应鼓励戒烟预防糖尿病。本研究结果发表于最新一期《糖尿病治疗》上(Diabetes Care December 2